Patent ID: 8124829

Claim:
A double-transgenic mouse derived from cross-breeding a transgenic mouse whose genome comprises a first DNA segment comprising: (a) a second DNA segment comprising a platelet derived growth factor B-chain promoter; and (b) a third DNA segment which encodes a human receptor for advanced glycation endproducts; wherein the second DNA segment is operatively linked to the third DNA segment and the first DNA segment is integrated into the genome of the mouse; and wherein said mouse exhibits a reduced amount of infarcted cerebral tissue following induction of a transient middle cerebral artery occlusion in the mouse as compared to the amount exhibited by an otherwise identical mouse lacking said first DNA segment, with a transgenic mouse whose genome comprises a fourth DNA segment comprising: (c) a fifth DNA segment comprising a platelet derived growth factor B-chain promoter; and (d) a sixth DNA segment which encodes a human amyloid precursor protein comprising a V717F mutation and a K670M/N671L mutation, wherein the fifth DNA segment is operatively linked to the sixth DNA segment and the fourth DNA segment is integrated into the genome of the mouse, and wherein the double-transgenic mouse expresses both human amyloid precursor protein comprising a V717F mutation and K670M/N671L mutation and a human receptor for advanced glycation endproducts, and wherein the double-transgenic mouse exhibits increased expression of phosphorylated tau as compared to an otherwise identical mouse lacking said first and fourth DNA segments.